Medical Laboratories & Research
Investopedia explains: Both pharma and biotech stocks are faced with a costly process ...
Agilent may be quite a bit stronger than its reported numbers would indicate.
Pricing Still A Long-Term Risk, But Illumina Continues To Build A Sequencing Fortress ...
Core operating performance at Agilent needs to improve